The AKIP1 Knockout A-549 Polyclonal Cells product consists of a polyclonal population of A-549 lung adenocarcinoma cells subjected to CRISPR/Cas9-mediated gene disruption targeting the AKIP1 locus. This polyclonal knockout model provides a heterogeneous pool of edited cells, enabling functional studies of AKIP1 deficiency within a physiologically relevant epithelial cancer background. By ablating AKIP1 expression, researchers can dissect its contributions to PKA-dependent signaling and cellular phenotypes without the confounding effects of clonal variation.
The A-549 cell line, originally isolated from the lung adenocarcinoma of a 58-year-old Caucasian male, is an adherent epithelial model widely used in cancer biology. These cells harbor wild-type p53 and express markers of alveolar type II pneumocytes, making them a relevant system for studying non-small cell lung cancer progression, drug metabolism, and respiratory disease. A-549 cells are frequently employed in anticancer drug screening and for dissecting signal transduction pathways due to their robust growth and genetic manipulability.
AKIP1 encodes a scaffold protein that directly binds the PKA catalytic subunit PRKACA, enhancing its enzymatic activity and amplifying phosphorylation of downstream effectors. Within the cAMP/PKA cascade, upstream signals from GPCRs, adenylyl cyclase, and ??-adrenergic agonists converge on AKIP1 to activate transcription factors CREB and NF-??B RELA. AKIP1 also forms complexes with IKBKG to modulate NF-??B pathways, affecting expression of survival genes and apoptotic regulators such as BAD. Through these interactions, AKIP1 promotes transcriptional programs that drive cell survival, proliferation, and hypertrophy, while intersecting with apoptosis regulation and ERK signaling.
In A-549 cells, basal PKA activity and NF-??B pathway components create a permissive environment for AKIP1-dependent oncogenic signaling. Disruption of AKIP1 enables precise uncoupling of its role in sustaining proliferation, suppressing apoptosis, and enhancing migration and invasion. This knockout model also facilitates evaluation of AKIP1-dependent modulation of sensitivity to genotoxic agents such as cisplatin, potentially revealing links between PKA hyperactivity and chemoresistance. Comparative analysis of knockout and wild-type pools thus illuminates the molecular underpinnings of lung adenocarcinoma aggressiveness.
Researchers can exploit this polyclonal knockout pool for comprehensive pathway interrogation. Western blotting for AKIP1 and phospho-CREB (Ser133), alongside RT-qPCR for PKA-responsive genes, validates target disruption and downstream signaling alterations. Proliferation and apoptosis are assessed via MTT and caspase-3/7 luminescence or Annexin V flow cytometry, while wound-healing and Transwell assays gauge migratory and invasive potential. NF-??B reporter assays and phospho-p65 immunofluorescence quantify transcriptional activity, and co-immunoprecipitation of PRKACA verifies loss of AKIP1-PKA binding. Additional analyses such as phospho-BAD and phospho-ERK immunoblotting further delineate apoptotic and survival signaling. Combined with cisplatin sensitivity profiling, these applications enable dissection of AKIP1’s contribution to tumor biology and therapeutic response. For further information, contact Ascent Research.
